Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shane Christensen

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Australian Family Physician|October 19, 2004
PCR analysisShane Christensen
Australian Family Physician|April 10, 2008
Supporting clinical teachers - a review of the literatureShane Christensen
The Pediatric Infectious Disease Journal|March 16, 2012
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of ageCynthia Nassim, Shane Christensen, Dan Henry, et al.
Vaccine|March 27, 2020
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United StatesLee-Jah Chang, James Hedrick, Shane Christensen, et al.
The Pediatric Infectious Disease Journal|August 28, 2020
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized StudyCarmen I Baccarini, Michael W Simon, Donald Brandon, et al.
Vaccine|March 7, 2015
Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccinationStan L Block, Shane Christensen, Bikash Verma, et al.
Human Vaccines & Immunotherapeutics|March 27, 2020
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized studyGermán Áñez, James Hedrick, Michael W Simon, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Australian Family Physician|October 19, 2004
PCR analysisShane Christensen
Australian Family Physician|April 10, 2008
Supporting clinical teachers - a review of the literatureShane Christensen
The Pediatric Infectious Disease Journal|March 16, 2012
Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of ageCynthia Nassim, Shane Christensen, Dan Henry, et al.
Vaccine|March 27, 2020
A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United StatesLee-Jah Chang, James Hedrick, Shane Christensen, et al.
The Pediatric Infectious Disease Journal|August 28, 2020
Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized StudyCarmen I Baccarini, Michael W Simon, Donald Brandon, et al.
Vaccine|March 7, 2015
Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccinationStan L Block, Shane Christensen, Bikash Verma, et al.
Human Vaccines & Immunotherapeutics|March 27, 2020
Immunogenicity and safety of a booster dose of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in adolescents and adults: a Phase III randomized studyGermán Áñez, James Hedrick, Michael W Simon, et al.
The Pediatric Infectious Disease Journal|March 15, 2016
A Phase 2, Randomized, Active-controlled, Observer-blinded Study to Assess the Immunogenicity, Tolerability and Safety of Bivalent rLP2086, a Meningococcal Serogroup B Vaccine, Coadministered With Tetanus, Diphtheria and Acellular Pertussis Vaccine and Serogroup A, C, Y and W-135 Meningococcal Conjugate Vaccine in Healthy US AdolescentsDerek Muse, Shane Christensen, Prakash Bhuyan, et al.
Vaccine|November 17, 2023
A phase 3 study evaluating the lot consistency, immunogenicity, safety, and tolerability of a Clostridioides difficile vaccine in healthy adults 65 to 85 years of ageShane Christensen, Salim Bouguermouh, Kumar Ilangovan, et al.
Pageof 1